Browse our 650+ Publications​

Latest Publications

Durable immune responses after BNT162b2 vaccination in home-dwelling old adults

Lena Hansen et al.
January 2023
Authors and Affiliates
Lena Hansen 1, Karl Albert Brokstad 1 2, Amit Bansal 1, Fan Zhou 1, Geir Bredholt 3, Therese Bredholt Onyango 1, Helene Heitmann Sandnes 3, Rebecca Elyanow 4, Anders Madsen 1, Mai-Chi Trieu 1, Marianne Sævik 5, Hanne Søyland 5, Jan Stefan Olofsson 1, Juha Vahokoski 1, Nina Urke Ertesvåg 1, Elisabeth Berg Fjelltveit 1, Shahin Shafiani 4, Camilla Tøndel 3 6 7, Heidi Chapman 4, Ian Kaplan 4, Kristin G I Mohn 1 5, Nina Langeland 3 5 8, Rebecca Jane Cox 1 9. 1 Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway. 2 Department of Safety, Chemistry and Biomedical Laboratory Sciences, Western Norway University of Applied Sciences, Bergen, Norway. 3 Department of Clinical Science, University of Bergen, Bergen, Norway. 4 Adaptive Biotechnologies, Seattle, WA, USA. 5 Department of Medicine, Haukeland University Hospital, Bergen, Norway. 6 Department of Pediatrics, Haukeland University Hospital, Bergen, Norway. 7 Department of Research and Innovation, Haukeland University Hospital, Bergen, Norway. 8 National Advisory Unit for Tropical Infectious Diseases, Haukeland University Hospital, Bergen, Norway. 9 Department of Microbiology, Haukeland University Hospital, Bergen, Norway.

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.

Dytfeld D, et al.
Lancet Oncology
January 2023
Authors and Affiliates
Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Tadeusz Kubicki, Paweł Robak, Adam Walter-Croneck, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Łukasz Szukalski, Agnieszka Końska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Oscar B Lahoud, Jeffrey A Zonder, Kent Griffith, Andrew Stefka, Ajay Major, Benjamin A Derman, Andrzej J Jakubowiak Poznan University of Medical Sciences, Poznan, Poland (D Dytfeld MD PhD, T Kubicki MD, A Nowicki MD PhD, T Szczepaniak MD, A Łojko-Dankowska MD PhD, M Matuszak MD PhD, Prof L Gil MD PhD); Wroclaw Medical University, Wroclaw, Poland (Prof T Wróbel MD PhD, J Rybka MD PhD, M Majcherek MD PhD, Prof L Usnarska-Zubkiewicz MD PhD); Institute of Hematology and Blood Transfusion, Warsaw, Poland (Prof K Jamroziak MD PhD, B Puła MD PhD, A Końska MD);Medical University of Lodz, Lodz, Poland (P Robak MD PhD, D Mikulski MD, Prof T Robak MD PhD); Medical University of Lublin, Lublin, Poland (A Walter-Croneck MD PhD, O Czabak MD PhD); Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland (J Czyż MD PhD, L Szukalski MD); Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland (A Tyczyńska MD, Prof J M Zaucha MD PhD); Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (A Druzd-Sitek MD PhD, Prof J Walewski MD PhD);Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland (Prof K Giannopoulos MD PhD);Memorial Sloan-Kettering Cancer Institute, New York, NY, USA (O B Lahoud MD);Karmanos Cancer Institute, Detroit, MI, USA(J A Zonder MD); University of Michigan, Ann Arbor, MI, USA(K Griffith MS); University of Chicago Medical Center, Chicago, IL, USA (A Stefka MS, A Major MD, B A Derman MD, Prof A J Jakubowiak PhD);University of Colorado School of Medicine, Aurora, CO, USA (A Major)

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.

Cohen AD, et al.
Blood
January 2023
Authors and Affiliates
Adam D. Cohen,1 María-Victoria Mateos,2 Yael C. Cohen,3 Paula Rodriguez-Otero,4 Bruno Paiva,4 Niels W.C.J. van de Donk,5 Thomas Martin,6 Attaya Suvannasankha,7 Kevin C. De Braganca,8 Christina Corsale,8 Jordan M. Schecter,8 Helen Varsos,8 William Deraedt,9 Liwei Wang,8 Martin Vogel,10 Tito Roccia,10 Xiaoying Xu,8 Pankaj Mistry,11 Enrique Zudaire,12 Muhammad Akram,13 Tonia Nesheiwat,13 Lida Pacaud,13 Irit Avivi,3 and Jesus San-Miguel4 1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; 2Hospital Clinico Universitario de Salamanca, Salamanca, Spain; 3Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 4Clinica Universidad de Navarra, CCUN, Centro de Investigación, Medica Aplicada (CIMA), Instituto de Investigación, Sanitaria de Navarra (IDISNA, CIBERONC), CIBER-ONC CB16/12/00369, Pamplona, Spain; 5Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands; 6UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; 7Indiana University Simon Cancer Center, Indiana University and Roudebush VAMC, Indianapolis, IN; 8Janssen R&D, Raritan, NJ; 9Janssen R&D, Beerse, Belgium; 10Janssen Global Services, LLC, Raritan, NJ; 11Janssen R&D, High Wycombe, United Kingdom; 12Janssen R&D, Springhouse, PA; and 13Legend Biotech USA, Piscataway, NJ

Characterisation of T cell receptor repertoires in coeliac disease

Lee LW, et al.
January 2023
Authors and Affiliates
Lik Wee Lee 1, Shahin Shafiani 1, Beryl Crossley 1, Ryan O Emerson 1, David Williamson 1, Anna Bunin 2, Justin Vargas 2, Arnold S Han 2, Ian M Kaplan 1, Peter H R Green 2, Ilan Kirsch 1, Govind Bhagat 3; 1Computational Biology and Translational Medicine, Adaptive Biotechnologies Corp, Seattle, Washington, USA. 2Department of Medicine, Celiac Disease Center, Columbia University Irving Medical Center, New York, New York, USA. 3Department of Pathology and Cell Biology and Department of Medicine, Celiac Disease Center, Columbia University Irving Medical Center, New York, New York, USA. gb96@cumc.columbia.edu

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.

Ramchandren R, et al.
The Lancet
December 2022
Authors and Affiliates
Radhakrishnan Ramchandren,a Peter Johnson,b Nilanjan Ghosh,c Jia Ruan,d Kirit M. Ardeshna,e Roderick Johnson,f Gregor Verhoef,g David Cunningham,h Sven de Vos,i Shireen Kassam,j Luis Fayad,k John Radford,l Sarah Bailly,m Fritz Offner,n David Morgan,o Javier Munoz,p,s Jerry Ping,q Edith Szafer-Glusman,q Karl Eckert,q Jutta K. Neuenburg,q and Andre Goy a Division of Hematology/Oncology, University of Tennessee Health Science Center, Knoxville, TN, USA b Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton, UK c Levine Cancer Institute, Atrium Health, Charlotte, NC, USA d Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA e University College London/UCL Hospitals, Biomedical Research Centre, London, UK f Leeds Cancer Centre at St. James’s University Hospital, Leeds, UK g Department of Haematology, UZ Leuven – Campus Gasthuisberg, Leuven, Belgium h Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust – Royal Marsden Hospital, London, UK i Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA j Haematology Department, King’s College Hospital, London, UK k Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA l Division of Cancer Sciences, The University of Manchester and the Christie NHS Foundation Trust, Manchester, UK m Cliniques Universitaires Saint-Luc, Université Catholique de Louvain Brussels, Brussels, Belgium n Department of Clinical Hematology, Universitair Ziekenhuis Gent, Ghent, Belgium o Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA p Department of Hematology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA q Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA r Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Thieblemont C, et al.
Journal of Clinical Oncology
December 2022
Authors and Affiliates
Catherine Thieblemont, MD, PhD1; Tycel Phillips, MD2; Herve Ghesquieres, MD, PhD3; Chan Y. Cheah, MBBS, DMSc4,5;Michael Roost Clausen, MD, PhD6; David Cunningham, MD7; Young Rok Do, MD, PhD8; Tatyana Feldman, MD9;Robin Gasiorowski,MBBS, PhD10; Wojciech Jurczak, MD, PhD11; Tae Min Kim, MD, PhD12; David John Lewis, MD13;Marjolein van der Poel, MD, PhD14; Michelle Limei Poon, MD15; Mariana Cota Stirner, MD, PhD16; Nurgul Kilavuz, MSc17;Christopher Chiu, PhD17; Menghui Chen, PhD17; Mariana Sacchi, MD17; Brian Elliott, MD17; Tahamtan Ahmadi, MD, PhD17;Martin Hutchings, MD, PhD18; and Pieternella J. Lugtenburg, MD, PhD19 1 Assistance Publique & Hopitaux de Paris (APHP), H ˆ opital Saint-Louis, ˆHemato-oncologie, Universit ´ e de Paris, Paris, France ´ 2 University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 3 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Benite, ´ France 4 Sir Charles Gairdner Hospital, Perth, Australia 5 Division of Internal Medicine, Medical School, University of Western Australia, Perth, Australia 6 Vejle Hospital, Vejle, Denmark 7 The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom 8 Keimyung University Dongsan Medical Center, Daegu, Republic of Korea 9 Hackensack Meridian Health Hackensack University Medical Center, Hackensack, NJ 10Concord Hospital, University of Sydney, Sydney, Australia 11MSC National Research Institute of Oncology, Krakow, Poland ´ 12 Seoul National University Hospital, Seoul, Republic of Korea 13 University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, United Kingdom 14 On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/ LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands 15 National University Hospital, Singapore 16 AbbVie, North Chicago, IL 17 Genmab, Princeton, NJ 18 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark 19 On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, the Netherlands

NoisET: Noise Learning and Expansion Detection of T-Cell Receptors

Koraichi MB, et al.
Journal of Physical Chemistry A
December 2022
Authors and Affiliates
Meriem Bensouda Koraichi 1, Maximilian Puelma Touzel 2, Andrea Mazzolini 1, Thierry Mora 1, Aleksandra M Walczak 1; 1 Laboratoire de physique de l' École normale supérieure, CNRS, PSL University, Sorbonne Université, and Université de Paris, Paris75005, France. 2 MILA, University of Montreal, MontrealH2S 3H1, Canada.

Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML

Fujii S, et al.
Molecular Therapy — Oncolytics
December 2022
Authors and Affiliates
Shin-ichiro Fujii 1,2,10, Toyotaka Kawamata 3,10, Kanako Shimizu 1,10, Jun Nakabayashi 4, Satoru Yamasaki 1, Tomonori Iyoda 1, Jun Shinga 1, Hiroshi Nakazato 1, An Sanpei 1, Masami Kawamura 1, Shogo Ueda 1, Jan Dörrie 5, Svetlana Mojsov 6, Madhav V. Dhodapkar 7, Michihiro Hidaka 8, Masanori Nojima 9, Fumitaka Nagamura 9, Shigemi Yoshida 2, Toshio Goto 2, and Arinobu Tojo 3; 1 Laboratory for Immunotherapy, RIKEN Center for Integrative Medical Science (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, Japan 2 Program for Drug Discovery and Medical Technology Platforms, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, Japan 3 Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo (IMSUT): Minato-ku, Tokyo, Japan 4 Department of Mathematics, Tokyo Medical and Dental University, Ichikawa, Chiba, Japan 5 Department of Dermatology, Universitätsklinikum Erlangen, Erlangen, Germany 6 The Rockefeller University, New York, NY, USA 7Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA, USA 8Department of Hematology/Oncology, National Hospital Organization Kumamoto Medical Center, Clinical Laboratory: Kumamoto, Kumamoto, Japan 9Center for Translational Research, The Institute of Medical Science, The University of Tokyo (IMSUT), Minato-ku, Tokyo, Japan

Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection

Win TS, et al.
JCI
November 2022
Authors and Affiliates
Thet Su Win 1,2, William J Crisler 1, Beatrice Dyring-Andersen 1, Rachel Lopdrup 2, Jessica E Teague 1, Qian Zhan 1, Victor Barrera 3, Shannan Ho Sui 3, Sotirios Tasigiorgos 2, Naoka Murakami 4, Anil Chandraker 4, Stefan G Tullius 5, Bohdan Pomahac 2, Leonardo V Riella 4, Rachael A Clark 1; 1 Department of Dermatology and. 2 Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3 Bioinformatics Core, Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 4 Schuster Transplantation Research Center and. 5 Division of Transplant Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Previous Next